Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Arctic Bioscience Director's Dealing 2025

Jan 13, 2025

3536_dirs_2025-01-13_c08928e9-6f86-40cf-994a-478223406b96.html

Director's Dealing

Open in viewer

Opens in your device viewer

Arctic Bioscience - Primary insiders participating in convertible loan facility

Arctic Bioscience - Primary insiders participating in convertible loan facility

Reference is made to the stock exchange release from earlier today, 13[th]

January 2025, regarding new funding, including a convertible loan facility of

NOK 15 million.

The following primary insiders, or closely related companies to primary

insiders, are a part of the total investor consortium:

· Ronja Capital Investment AS, a company closely related to Board Member Tore

Tønseth, NOK 3,0 million

· Vartdal Holding AS, a company closely related to Board Member Jan Endre

Vartdal, NOK 1,0 million

· Brødrene Vartdal AS, a company closely related to Board Member Jan Endre

Vartdal, NOK 1,0 million

· Ajea Invest AS, a company closely related to Board Member Asbjørn

Solevågseide, NOK 0,5 million

· Eros AS, a company closely related to Board Member Per Magne Eggesbø, NOK

0,6 million

· Siglar AS, a company closely related to Chairman of the Board Harald Nordal,

NOK 0,15 million

· Clu Invest AS, a company closely related to CEO Christer L. Valderhaug, NOK

0,1 million

· Runhild Gammelsæter, Medical Director, NOK 0,05 million

This information is subject to the disclosure requirements pursuant to

Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act

§ 5-12.

For more information, please contact:

Jone R. Slinning

CFO

Phone: +47 948 75 469

E-mail: [email protected]

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.